Applying Wilson and Jungner Criteria to Liver Disease Screening

The feasibility of screening for advanced steatotic liver disease is being evaluated to determine if early detection can prevent severe health outcomes. According to an analysis published in The Lancet on April 11, 2026, the potential for early detection is only viable if such screening is linked to effective intervention.

Medical researchers are assessing these screening programs through the lens of the Wilson and Jungner criteria. These basic criteria for the usefulness of screening procedures were formulated in 1968 in a paper by the World Health Organization.

The Application of Screening Criteria

Liver disease is described as a curious case when applying the Wilson and Jungner principles. There are strong rationales supporting the need for screening, primarily because the disease often has a long asymptomatic phase.

Because the disease may not present symptoms for a significant period, patients often present for medical care only in late stages, which is associated with very poor outcomes.

Challenges to Implementation

Despite the potential benefits of early detection, several factors complicate the implementation of a standardized screening program. There is currently no consensus on which individuals have a clinically relevant disease or who should be prioritized for treatment.

the analysis notes that the most accurate non-invasive testing approaches may actually undermine the justifications for these screening programs.

Supporting the rationale for screening is the long-asymptomatic phase of disease and the very poor outcomes for late presentations. However, there is no consensus about who has a clinically relevant disease and who gets treatment, and the most accurate non-invasive testing approach undermines these justifications.

The Lancet

Clinical Context and Related Conditions

The discussion regarding who and when to screen for liver disease often intersects with other metabolic health conditions. This includes the screening and treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), prediabetes, and type 2 diabetes.

The central goal remains the identification of advanced steatotic liver disease early enough to implement interventions that can alter the trajectory of the disease and prevent severe complications.